Global Family Office BioForum Joins RESI Asia

Interview with Chuck Stetson, CEO of Stetson Family Office

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Click to see part one of a two part interview with Chuck Stetson, CEO, Stetson Family Office and Founder of the Global Family Office BioForum (GFOB). Chuck, who is the third generation running the Stetson Family Office, is an entrepreneur, venture capitalist, and philanthropist. GFOB helps make more high quality investments in the life science arena by connecting regional family offices with regional angel groups, incubators and accelerators – essentially helping family offices around the globe participate in the funding of early stage technology assets located in their local healthcare tech hubs.

This interview, conducted by Dennis Ford, CEO, Life Science Nation and Creator of the Redefining Early Stage Investments (RESI) Conference Series, is a deep dive into how a family office views and participates in funding startups. Chuck will be representing the GFOB at both RESI Asia events – Shanghai, November 12^th and Taipei, November 14^th. Click here to register for the events.

Comments Leave a Comment
Categories Redefining Early Stage Investments

Hot Mandates

Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease

The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need

The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
Hot Investor Mandate 3: Strategic Investment Firm of Large Pharma Invests in Early and Late Stage Therapeutics & Drug-Device Combinations, Especially Interested in Orphan and Rare Diseases

A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
Hot Investor Mandate 4: USA-Based Investment Firm Can Invest Over $10M in Innovative Medtech and Digital Health Companies Based in Texas or Southwestern USA

The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health

A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]

Featured: All About Innovation Challenge

Call for Innovation Challenge Applicants

Companies from all categories of life science are encouraged to apply to Innovation Challenge for RESI Healthtech Week. Eligible companies can apply to Day 1 the First Coast Innovator’s Gathering, Day 2 RESI Global Partnering or both. Applicants will have the opportunity for excellent visibility among investors and strategic partners.
RESI Healthtech Week Announces the First Coast Innovation Challenge on September 5th, And the RESI Global Innovation Challenge on September 6th

By Samuel Rubin, Business Development Manager, LSN For the first time this fall, Life Science Nation (LSN) will have two days of competition as part of the RESI Healthtech Week (September 5-7, 2018). Day 1 will feature the First Coast Innovation Challenge, where the top 10 ranked companies of the First Coast tech hubs will present […]
RESI Innovation Challenge: Meet The Asia-Based Startups That Took The Top Spots At RESI Boston Summer

By Jessica Yang, Investor Research Analyst, LSN On June 4th, more than 700 scientist-entrepreneurs and investors entered the exhibition hall at Boston Marriott Copley Place to participate in the RESI conference. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and digital health sectors. The 30 companies, evaluated by LSN’s expert […]
RESI Boston Summer Presents Innovation Challenge Finalists From Around The World

By James Huang, Research Analyst, LSN We are excited to showcase the top RESI Innovation Challenge startup applicants, who will be taking part in the poster presentation showcase at the second annual RESI BIO held in Boston this year, alongside the BIO International conference. These handpicked companies represent the key sectors of the healthcare space […]
How to Use the RESI Innovation Challenge to Build Success for Your Company: An Interview with RESI Winner Steven ten Holder (Acorn Biolabs)

An interview with Steven ten Holder, COO, Acorn Biolabs – By Greg Mannix, VP of International Business Development, LSN This year’s 2nd place finisher at the Innovation Challenge at RESI on MaRS was Acorn Biolabs. LSN interviewed COO, Steven ten Holder and got some key takeaways on how Acorn used the RESI Innovation Challenge effectively: […]

Search

Global Family Office BioForum Joins RESI Asia

Interview with Chuck Stetson, CEO of Stetson Family Office

Leave a Reply Cancel reply

Popular Topics

Hot Mandates

Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease

Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need

Hot Investor Mandate 3: Strategic Investment Firm of Large Pharma Invests in Early and Late Stage Therapeutics & Drug-Device Combinations, Especially Interested in Orphan and Rare Diseases

Hot Investor Mandate 4: USA-Based Investment Firm Can Invest Over $10M in Innovative Medtech and Digital Health Companies Based in Texas or Southwestern USA

Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health

Featured: All About Innovation Challenge

Call for Innovation Challenge Applicants

RESI Healthtech Week Announces the First Coast Innovation Challenge on September 5th, And the RESI Global Innovation Challenge on September 6th

RESI Innovation Challenge: Meet The Asia-Based Startups That Took The Top Spots At RESI Boston Summer

RESI Boston Summer Presents Innovation Challenge Finalists From Around The World

How to Use the RESI Innovation Challenge to Build Success for Your Company: An Interview with RESI Winner Steven ten Holder (Acorn Biolabs)

LSN Twitter

Contact us

Archives

Subscribe

Life Science Nation

RESI Conference Series

Investor Platform Demo

Company Platform Demo

Follow Us

Learn More

Site Map

Search

Interview with Chuck Stetson, CEO of Stetson Family Office

Share this:

Share this:

Like this:

Related

Leave a Reply Cancel reply

Popular Topics

Hot Mandates

Featured: All About Innovation Challenge

Contact us

Archives

Subscribe

Life Science Nation

RESI Conference Series

Investor Platform Demo

Company Platform Demo

Follow Us

Learn More

Site Map